Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | RAD52 | P43351 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | MPO | P05164 | 2/20 | 0.64 |
| ▸ | SLC9A3 | P48764 | 8/20 | 0.57 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.54 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697414 | 0.92 | POLB (0.68) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6700271 | 0.90 | POLB (0.65) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6695186 | 0.88 | KMT2A (0.77) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6696132 | 0.87 | KMT2A (0.85) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6695760 | 0.83 | KMT2A (0.97) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6695605 | 0.83 | KMT2A (0.73) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6701115 | 0.82 | KMT2A (0.77) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6701162 | 0.82 | KMT2A (0.77) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6700380 | 0.82 | KMT2A (0.72) | KMT2ARAD52POLBMPOSLC9A3 | |
| SCHEMBL6698132 | 0.81 | RAD52 (0.70) | KMT2ARAD52POLBMPOSLC9A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | NHERF1, SLC9A3, SLC9A1 | KMT2A 3326/4885RAD52 4856/4885POLB 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.